0
Controversies in Neurology |

Treatment of Ocular Myasthenia:  Steroids Only When Compelled

Henry J. Kaminski, MD; Robert B. Daroff, MD
Arch Neurol. 2000;57(5):752-753. doi:10.1001/archneur.57.5.752.
Text Size: A A A
Published online

Extract

MYASTHENIA gravis (MG) preferentially involves the ocular muscles.1 Ocular myasthenia manifests as weakness of the levator palpebrae superioris leading to ptosis, or the extraocular muscles producing diplopia. The precise reasons for this predilection are poorly understood.23 As with all therapies for MG, there are few well-controlled studies of treatments of ocular myasthenia.4 Immunosuppressive therapies, in particular the corticosteroid prednisone, are the mainstay of treatment for generalized MG that compromises an individual's daily activities. Prednisone is also commonly used for ocular myasthenia. However, 4 factors should be considered prior to the use of steroids for patients with MG isolated to the ocular muscles: (1) Could the patient's symptoms improve with safer forms of therapy? (2) Will steroid treatment lead to resolution of symptoms? (3) Does the severity of the symptoms warrant the risk of steroid adverse effects? (4) Do steroids reduce the chance of generalization? We consider each of these questions and reach the conclusion that only the occasional case of ocular myasthenia should be treated with steroids.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
[Immunosuppressive therapy of myasthenias].
Med Welt 1973;;24(23):955-63.
[MYASTHENIAS: THYMECTOMY AND SPIRONOLACTONES].
Rev Otoneuroophtalmol 1964 Jul-Aug;;36():169-74.
Jobs